UT San Antonio
UT Health San Antonio
210-567-7000 Give
Category ID
171

Ivanhoe.com: Fast tracked leukemia drug saves lives

<p>Dr. Ruben Mesa, executive director of the Mays Cancer Center, is shown in an interview he gave this spring that recently appeared on stations nationwide. Watch Video</p>

Share This Story

UT Health San Antonio surgical oncologist co-authors NEJM article showing disparity in Black breast cancer mortality

<p>Black women die of breast cancer at rates nearly 40% higher than white women, despite having lower instances of the disease, because of racial disparities in care, according to a New England Journal of Medicine article by a UT Health San Antonio surgical oncologist and two American Cancer Society scientists. The authors, led by Ismail [&hellip;]</p>

Share This Story

Welcoming our new chief of surgical oncology

<p>Alexander Parikh MD, MPH, FACS, FSSO, has joined the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center as chief of surgical oncology in the Division of Surgical Oncology and Endocrine Surgery. Dr. Parikh is a professor of surgery and holds the Paige Johnson Distinguished Chair of Oncology and is the [&hellip;]</p>

Share This Story

KXAN-TV, Austin: Susan G. Komen® invests $21.7 million in research focused on improving outcomes for breast cancer patients

<p>Dr. Amelie G. Ramirez, Population Health Sciences and Institute for Health Promotion Research, is listed as a grant winner in this article. &nbsp; Read More</p>

Share This Story

Pheo Para Alliance recognizes UT Health San Antonio as rare disease Center of Excellence

<p>Pheo Para Alliance, a patient advocacy organization dedicated to supporting those with pheochromocytoma (pheo) and paraganglioma (para), a rare neuroendocrine tumor, has designated The University of Texas Health Science Center at San Antonio (UT Health San Antonio) as a Pheo Para Center of Excellence. The Center of Excellence Program recognizes institutions worldwide for providing cutting-edge, quality, multidisciplinary care and [&hellip;]</p>

Share This Story

New Surgical Clinical Trial Recruiting Women with BRCA1 Mutations at High Risk for Ovarian Cancer

<p>A New Ovarian Cancer Clinical Trial at UT Health San Antonio MD Anderson Cancer Center is Investigating Efficacy of Surgical Pathways for Women Harboring High-Risk BRCA1 Genetic Mutations Women harboring mutations in the BRCA1 gene face an incredibly high risk of developing ovarian cancer during their lifetime and much higher risks for peritoneal cancer and [&hellip;]</p>

Share This Story

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

<p>ERX-41, developed by UT Health San Antonio scientists, exploits a previously unrecognized weakness in breast cancer and other solid tumors. Media contact: Will Sansom, 210-567-2579, Sansom@uthscsa.edu SAN ANTONIO (June 2, 2022) – A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer [&hellip;]</p>

Share This Story

Brian Fricke, MD, shares 6 Steps to Starting Exercise After Cancer Treatment

<p>In honor of cancer survivor’s month, I thought I would share some tips about getting back to exercise after cancer treatment. I also would encourage anyone battling cancer to read these tips, as early research suggests that physical activity during cancer treatment may improve symptoms related to cancer and its treatment. It may also enhance recovery [&hellip;]</p>

Share This Story

Mays Cancer Center has large presence at ASCO Annual Meeting

<p>Investigators from the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer, are presenting multiple research abstracts at this week’s Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Topics and links to abstracts are below. Congratulations to all Mays Cancer Center researchers for this fine work. Impact of [&hellip;]</p>

Share This Story

Oral pill improves care of patients with bone marrow cancer: Study

<p>Results of MOMENTUM myelofibrosis clinical trial presented at ASCO 2022 Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu CHICAGO AND SAN ANTONIO (June 7, 2022) — Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, [&hellip;]</p>

Share This Story

Subscribe to Cancer